Infliximab

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2) . Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2]. The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Product Specifications

CAS Number

[170277-31-3]

Product Name Alternative

Avakine; CT-P13; SB2; TA-650

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/infliximab.html

Purity

90.30

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[Infliximab]

Molecular Weight

(145.98 kDa)

References & Citations

[1]Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88 (5) :e12716.|[2]Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301 (5) :E844-52.